Literature DB >> 8920936

2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin.

H Attalla1, T P Mäkelä, H Adlercreutz, L C Andersson.   

Abstract

The endogenous estrogen metabolite 2-methoxyestradiol (2-MeOE2) suppresses experimental tumor growth in vivo and inhibits angiogenesis activity in vitro. Moreover, 2-MeOE2 has been observed to block mitosis in cell cultures. As high concentrations of 2-MeOE2 prevent microtubule assembly in vitro, the mitotic arrest has been attributed to inhibition of tubulin polymerization. Here we report that concentrations of 2-MeOE2 that cause complete metaphasal arrest do not inhibit the assembly of mitotic spindles. In contrast to the chromosomal dispersal seen in cells arrested by the tubulin depolymerizing drug colcemid, the chromosomes of cells treated with 2-MeOE2 remained in the metaphasal plate indicating a functional defect of the mitotic spindle. The 2-MeOE2 arrest resembles those induced by compounds affecting microtubule dynamics such as taxol and vinblastine. The 2-MeOE2 block is also similar to that induced by several anti-calmodulin agents. Given that metaphase to anaphase transition is a calmodulin-dependent step and our observation that 2-MeOE2 inhibits calmodulin activity in vitro, we suggest that the 2-MeOE2 metaphasal arrest may occur via inhibition of calmodulin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920936     DOI: 10.1006/bbrc.1996.1683

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Negative regulation of the endocytic adaptor disabled-2 (Dab2) in mitosis.

Authors:  David Chetrit; Lior Barzilay; Galit Horn; Tom Bielik; Nechama I Smorodinsky; Marcelo Ehrlich
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

2.  2-Methoxyestradiol blocks the RhoA/ROCK1 pathway in human aortic smooth muscle cells.

Authors:  Lisa Rigassi; Federica Barchiesi Bozzolo; Eliana Lucchinetti; Michael Zaugg; Jürgen Fingerle; Marinella Rosselli; Bruno Imthurn; Edwin K Jackson; Raghvendra K Dubey
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-10-20       Impact factor: 4.310

3.  A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.

Authors:  Justine Yang Bruce; Jens Eickhoff; Roberto Pili; Theodore Logan; Michael Carducci; Jamie Arnott; Anthony Treston; George Wilding; Glenn Liu
Journal:  Invest New Drugs       Date:  2010-12-22       Impact factor: 3.850

4.  A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Authors:  Michael R Harrison; Noah M Hahn; Roberto Pili; William K Oh; Hans Hammers; Christopher Sweeney; Kyungmann Kim; Scott Perlman; Jamie Arnott; Carolyn Sidor; George Wilding; Glenn Liu
Journal:  Invest New Drugs       Date:  2010-05-25       Impact factor: 3.850

5.  Cytotoxic effect of achatinin(H) (lectin) from Achatina fulica against a human mammary carcinoma cell line (MCF7).

Authors:  Indra Dharmu; N Ramamurty; Ramalingam Kannan; Mary Babu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-09-18       Impact factor: 2.416

6.  Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation.

Authors:  Christina Batsi; Soultana Markopoulou; Evangelos Kontargiris; Christiana Charalambous; Christoforos Thomas; Savvas Christoforidis; Panagiotis Kanavaros; Andreas I Constantinou; Kenneth B Marcu; Evangelos Kolettas
Journal:  Biochem Pharmacol       Date:  2009-03-27       Impact factor: 5.858

7.  2-Methoxyestradiol, an endogenous metabolite of 17beta-estradiol, inhibits adipocyte proliferation.

Authors:  C Picó; P Puigserver; P Oliver; A Palou
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

Review 8.  Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Authors:  William D Figg; Erwin A Kruger; Douglas K Price; Sonia Kim; William D Dahut
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

9.  Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Authors:  Amye J Tevaarwerk; Kyle D Holen; Dona B Alberti; Carolyn Sidor; Jamie Arnott; Check Quon; George Wilding; Glenn Liu
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol.

Authors:  Hye Joung Choi; Bao Ting Zhu
Journal:  Biochim Biophys Acta       Date:  2012-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.